Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Status:
RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.